Our Drivers

Charlie Kimball completed his fifth Verizon IndyCar Series season in the No. 83 NovoLog FlexPen Chevrolet in 2015.  He returns to Novo Nordisk Chip Ganassi Racing in 2016 for his sixth season looking to continue to build upon last year’s campaign.

The Partnership

Novo Nordisk's Partnership: 

Novo Nordisk Chip Ganassi Racing was formed before the 2011 IndyCar Series season with driver Charlie Kimball – a Type-1 diabetic. Novo Nordisk, a world leader in diabetes care returns for a fourth season to continue to raise the level of diabetes awareness in the country and encourage people to talk to their healthcare provider about diabetes. Kimball enters his fourth season as the driver of the No. 83 NovoLog FlexPen Chevrolet and is coming off a season that saw him score a career-best 10 top-10 finishes and earn his first career win at Mid-Ohio.

About Novo Nordisk: 

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 37,200 employees in 76 countries, and markets its products in more than 180 countries.

Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).